Robert W. Baird analyst Eric Coldwell maintained a Hold rating on PPD (NASDAQ:PPD) on Tuesday, setting a price target of $48, which is approximately 3.90% above the present share price of $46.2.
Coldwell expects PPD to post earnings per share (EPS) of $0.21 for the second quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Hold rating of shares in PPD, with an average price target of $46.25.
The analysts price targets range from a high of $48 to a low of $40.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.36 billion and a net profit of $166.58 million. The company's market cap is $16.21 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.8% and a 63.20% success rate.
PPD, Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.